Luca Castagna

List of Publications by Year in Descending Order

244 papers	4,855 citations	34 h-index	57 g-index
272 ext. papers	5,879 ext. citations	3.9 avg, IF	4.94 L-index

#	Paper	IF	Citations
244	Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant Cyclophosphamide.. *Frontiers in Immunology*, **2021**, 12, 816231	8.4	1
243	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. *Leukemia*, **2021**, 35, 2672-2683	12.8	15
242	Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. *Transplantation and Cellular Therapy*, **2021**, 27, 492.e1-492.e6		2
241	Chemotherapy-based versus chemotherapy-free stem cell mobilization (+ plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. *Bone Marrow Transplantation*, **2021**, 56, 1876-1887	4.4	2
240	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. *Bone Marrow Transplantation*, **2021**, 56, 1842-1849	4.4	0
239	Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. *Transplantation and Cellular Therapy*, **2021**, 27, 478.e1-478.e5		2
238	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. *Transplantation and Cellular Therapy*, **2021**, 27, 328.e1-328.e6		
237	Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT. *JCI Insight*, **2021**, 6,	9.9	4
236	Single-cell profiling reveals the dynamics of cytomegalovirus-specific T cells in haploidentical hematopoietic stem cell transplantation. *Haematologica*, **2021**, 106, 2768-2773	6.6	2
235	Development of an Immobilization Device for Total Marrow Irradiation. *Practical Radiation Oncology*, **2021**, 11, e98-e105	2.8	6
234	Acute Graft-versus-Host-Disease Other Than Typical Targets: Between Myths and Facts. *Transplantation and Cellular Therapy*, **2021**, 27, 115-124		5
233	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). *American Journal of Hematology*, **2021**, 96, 69-79	7.1	11
232	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT. *Bone Marrow Transplantation*, **2021**, 56, 655-663	4.4	1
231	Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. *Bone Marrow Transplantation*, **2021**, 56, 883-889	4.4	2
230	Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. *Bone Marrow Transplantation*, **2021**, 56, 2763-2770	4.4	4
229	Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies. *Transplantation and Cellular Therapy*, **2021**, 27, 912.e1-912.e6		0
228	Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. *Transplantation and Cellular Therapy*, **2021**, 27, 999.e1-999.e1		2

227	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. *Journal of Hematology and Oncology*, **2020**, 13, 46	22.4	24
226	Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 617-623	2	4
225	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. *Journal of Clinical Oncology*, **2020**, 38, 1518-1526	2.2	16
224	Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 296-304	2	3
223	Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. *Cancer Medicine*, **2020**, 9, 52-61	4.8	10
222	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. *British Journal of Haematology*, **2020**, 188, 745-756	4.5	10
221	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 936-942	4.7	9
220	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 2299-2305	4.7	2
219	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1915-1922	4.7	14
218	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. *BMC Cancer*, **2020**, 20, 1140	4.8	4
217	Haploidentical Stem Cell Transplantation in Lymphomas-Expectations and Pitfalls. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
216	Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes. *Journal of Blood Medicine*, **2020**, 11, 389-403	2.3	2
215	Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. *Blood Advances*, **2020**, 4, 3900-3912	7.8	12
214	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2020**, 55, 12-24	4.4	46
213	Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2020**, 55, 349-355	4.4	8
212	Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. *Blood Advances*, **2020**, 4, 136-140	7.8	12
211	Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. *Blood Advances*, **2020**, 4, 1242-1249	7.8	10
210	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. *Haematologica*, **2020**, 105, 47-58	6.6	25

209	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. *Frontiers in Immunology*, **2020**, 11, 613954	8.4	1
208	Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2514-2516	4.7	3
207	The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide. *Bone Marrow Transplantation*, **2019**, 54, 1164-1167	4.4	3
206	Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide. *European Journal of Haematology*, **2019**, 102, 357-367	3.8	5
205	Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1810-1817	4.7	10
204	Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. *Bone Marrow Transplantation*, **2019**, 54, 1730-1737	4.4	15
203	Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1395-1406	4.7	15
202	Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease (GVHD): A Study on Behalf of the Acute Leukemia Working Party of EBMT.. *Biology of Blood and Marrow*	4.7	2
201	Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 cells. *British Journal of Haematology*, **2019**, 185, 570-573	4.5	10
200	T-Cell Replete Haploidentical Transplantation **2019**, 99-123		1
199	THE EFFICACY OF IBRUTINIB IN PATIENTS WITH RELAPSED MANTLE CELL LYMPHOMA AFTER FIRST LINE INTENSIVE CHEMO-IMMUNOTHERAPY AND ASCT A RETROSPECTIVE STUDY FROM THE LWP-EBMT. *Hematological Oncology*, **2019**, 37, 243-244	1.3	0
198	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. *Blood*, **2019**, 134, 775-775	2.2	5
197	Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT. *Blood*, **2019**, 134, 4018-4018	2.2	2
196	Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT. *Blood*, **2019**, 134, 3274-3274	2.2	
195	Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients. *Blood*, **2019**, 134, 4625-4625	2.2	
194	Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT. *Blood*, **2019**, 134, 701-701	2.2	1
193	Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide. *Blood*, **2019**, 134, 598-598	2.2	
192	CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy. *Blood*, **2019**, 134, 4484-4484	2.2	

191	Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma. *Blood*, **2019**, 134, 4614-4614	2.2	
190	Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies. *Blood*, **2019**, 134, 4503-4503	2.2	
189	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. *Blood Advances*, **2019**, 3, 360-369	7.8	59
188	CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLANTATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES. *Hematological Oncology*, **2019**, 37, 298-299	1.3	
187	HOW TO SELECT DONOR, STEM CELL SOURCE, AND CONDITIONING REGIMEN FOR HAPLOIDENTICAL TRANSPLANTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR LYMPHOMA: A REPORT OF THE EBMT LWP. *Hematological Oncology*, **2019**, 37, 299-300	1.3	
186	IMPACT OF CLASS II HLA MISMATCH ON CLINICAL OUTCOMES IN HODGKIN LYMPHOMA PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY). *Hematological Oncology*, **2019**, 37, 300-301	1.3	
185	Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. *Bone Marrow Transplantation*, **2019**, 54, 1067-1076	4.4	16
184	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. *Cancer*, **2019**, 125, 90-98	6.4	11
183	Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3K/□Inhibitor RP6530. *Clinical Cancer Research*, **2019**, 25, 1098-1112	12.9	35
182	HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1449-1454	4.7	25
181	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. *British Journal of Haematology*, **2018**, 181, 86-96	4.5	14
180	A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling. *Transplant Infectious Disease*, **2018**, 20, e12906	2.7	2
179	Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. *Cancer*, **2018**, 124, 1428-1437	6.4	78
178	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. *Bone Marrow Transplantation*, **2018**, 53, 255-263	4.4	8
177	Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. *Bone Marrow Transplantation*, **2018**, 53, 366-370	4.4	1
176	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. *Bone Marrow Transplantation*, **2018**, 53, 422-430	4.4	15
175	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. *Bone Marrow Transplantation*, **2018**, 53, 521-534	4.4	94
174	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. *Bone Marrow Transplantation*, **2018**, 53, 1522-1531	4.4	13

173	The early expansion of anergic NKG2A/CD56/CD16 natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation. *Haematologica*, **2018**, 103, 1390-1402	6.6	47
172	Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. *American Journal of Hematology*, **2018**, 93, 769-777	7.1	16
171	Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. *Bone Marrow Transplantation*, **2018**, 53, 1096-1104	4.4	12
170	High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. *American Journal of Hematology*, **2018**	7.1	15
169	Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study. *Blood*, **2018**, 132, 1655-1655	2.2	1
168	Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma. *Oncotarget*, **2018**, 9, 22741-22748	3.3	6
167	Influence of Donor Type, Stem Cell Source and Conditioning Regimen on Transplant Outcomes after Haploidentical Transplant with Post Transplant Cyclophosphamide for Lymphoma: A Report of the EBMT Lymphoma Working Party. *Blood*, **2018**, 132, 484-484	2.2	
166	Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate. *Blood*, **2018**, 132, 2185-2185	2.2	
165	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Mantle Cell Lymphoma Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis. *Blood*, **2018**, 132, 5748-5748	2.2	1
164	Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease: A Study on Behalf of the Acute Leukemia Working Party of EBMT. *Blood*, **2018**, 132, 4586-4586	2.2	0
163	Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma. *Blood*, **2018**, 132, 1628-1628	2.2	
162	Which Is the Best Mobilizing Regimen in POEMS Syndrome? a Retrospective Italian Study of Two Haematological Centres. *Blood*, **2018**, 132, 5692-5692	2.2	0
161	Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 549-554	4.7	26
160	T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 627-632	4.7	32
159	T-cell-replete haploidentical transplantation in acute myeloid leukemia. *Experimental Hematology*, **2018**, 58, 5-16	3.1	3
158	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). *Bone Marrow Transplantation*, **2017**, 52, 955-961	4.4	16
157	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. *Blood*, **2017**, 129, 1380-1388	2.2	167
156	Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. *Bone Marrow Transplantation*, **2017**, 52, 689-696	4.4	22

155	Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. *Bone Marrow Transplantation*, **2017**, 52, 683-688	4.4	32
154	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1549-1554	4.7	21
153	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. *Expert Opinion on Biological Therapy*, **2017**, 17, 821-836	5.4	3
152	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. *Bone Marrow Transplantation*, **2017**, 52, 620-621	4.4	16
151	Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. *Journal of Clinical Oncology*, **2017**, 35, 3425-3432	2.2	100
150	Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patients. *British Journal of Haematology*, **2017**, 176, 132-135	4.5	12
149	The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. *Bone Marrow Transplantation*, **2017**, 52, 135-137	4.4	10
148	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. *Clinical Infectious Diseases*, **2017**, 65, 1884-1896	11.6	63
147	Severe Cytokine Release Syndrome Is a Fatal Complication after PBSC, but Not after BM Haploidentical Transplantation with Post-Transplant Cyclophosphamide. *Blood*, **2017**, 130, 665-665	2.2	0
146	Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. *Bone Marrow Transplantation*, **2016**, 51, 1599-1601	4.4	32
145	The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. *Leukemia*, **2016**, 30, 2402-2405	10.7	12
144	Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation. *Scientific Reports*, **2016**, 6, 35745	4.9	12
143	Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. *Bone Marrow Transplantation*, **2016**, 51, 1644-1646	4.4	3
142	Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *Annals of Oncology*, **2016**, 27, 2251-2257	10.3	31
141	Bone marrow donor-related variables associated with harvest outcome in HLA-haploidentical transplantation with postinfusion cyclophosphamide. *Vox Sanguinis*, **2016**, 111, 93-100	3.1	3
140	Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. *Bone Marrow Transplantation*, **2016**, 51, 462-5	4.4	4
139	The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. *Leukemia and Lymphoma*, **2016**, 57, 2315-20	1.9	4
138	Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT. *Annals of Oncology*, **2016**, 27, 1088-1094	10.3	25

137	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. *Bone Marrow Transplantation*, **2016**, 51, 194-8	4.4	16
136	Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 119-24	4.7	74
135	Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis. *Blood*, **2016**, 128, 1165-1165	2.2	6
134	Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. *Journal of Clinical Oncology*, **2016**, 34, 3293-9	2.2	66
133	Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation. *Transfusion*, **2016**, 56, 1096-1100	2.9	7
132	Donor lymphocyte infusion after allogeneic stem cell transplantation. *Transfusion and Apheresis Science*, **2016**, 54, 345-55	2.4	36
131	Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. *Bone Marrow Transplantation*, **2016**, 51, 1032-40	4.4	21
130	Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. *Leukemia*, **2016**, 30, 2086-2089	10.7	33
129	Human Herpesvirus 6 replication predicts Cytomegalovirus reactivation after allogeneic stem cell transplantation from haploidentical donor. *Journal of Clinical Virology*, **2016**, 84, 24-26	14.5	15
128	The patient CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. *Bone Marrow Transplantation*, **2016**, 51, 1134-6	4.4	17
127	Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. *Transplant Infectious Disease*, **2015**, 17, 242-9	2.7	96
126	Plan robustness in field junction region from arcs with different patient orientation in total marrow irradiation with VMAT. *Physica Medica*, **2015**, 31, 677-82	2.7	24
125	Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. *Oncologist*, **2015**, 20, 323-8	5.7	25
124	In-vivo dosimetry with Gafchromic films for multi-isocentric VMAT irradiation of total marrow lymph-nodes: a feasibility study. *Radiation Oncology*, **2015**, 10, 86	4.2	13
123	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. *Blood*, **2015**, 125, 2855-64	2.2	100
122	Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. *Leukemia*, **2015**, 29, 686-8	10.7	48
121	Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. *Cancer*, **2015**, 121, 1809-16	6.4	28
120	Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. *Bone Marrow Transplantation*, **2015**, 50, 865-7	4.4	8

119	Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit. *Journal of Critical Care*, **2015**, 30, 1107-13	4	19
118	B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY. *Bone Marrow Transplantation*, **2015**, 50, 317-9	4.4	8
117	Primary refractory and early-relapsed Hodgkin lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. *Journal of Pathology*, **2015**, 237, 4-13	9.4	28
116	Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. *Haematologica*, **2015**, 100, 269-74	6.6	22
115	Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. *Haematologica*, **2015**, 100, e423-7	6.6	5
114	Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. *Mediterranean Journal of Hematology and Infectious Diseases*, **2015**, 7, e2015015	3.2	10
113	Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide. *Mediterranean Journal of Hematology and Infectious Diseases*, **2015**, 7, e2015048	3.2	6
112	High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. *Bone Marrow Transplantation*, **2015**, 50, 499-504	4.4	8
111	Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin lymphoma. *Bone Marrow Transplantation*, **2014**, 49, 190-4	4.4	117
110	First-line extracorporeal photochemotherapy for acute GVHD after unmanipulated haploidentical BMT following nonmyeloablative conditioning and post transplantation CY. *Bone Marrow Transplantation*, **2014**, 49, 317-8	4.4	7
109	A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. *American Journal of Hematology*, **2014**, 89, 83-7	7.1	20
108	Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors. *Bone Marrow Transplantation*, **2014**, 49, 1246-7	4.4	1
107	Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. *Bone Marrow Transplantation*, **2014**, 49, 1475-80	4.4	38
106	Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1560-5	4.7	10
105	Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 370-4	4.7	37
104	Bendamustine combined with donor lymphocytes infusion in Hodgkin lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1444-7	4.7	18
103	National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. *Leukemia and Lymphoma*, **2014**, 55, 1106-12	1.9	21
102	Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. *Haematologica*, **2014**, 99, 1762-8	6.6	24

101	Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 724-9	4.7	120
100	Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 501-6	4.7	7
99	Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1026-32	4.7	24
98	TLI in refractory chronic GVHD. *Bone Marrow Transplantation*, **2013**, 48, 854-8	4.4	6
97	Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. *Cancer*, **2013**, 119, 986-92	6.4	51
96	Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience. *Experimental Hematology*, **2013**, 41, 17-27	3.1	5
95	Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 576-83	4.7	1
94	Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: a case report. *Transfusion and Apheresis Science*, **2013**, 49, 205-7	2.4	
93	Impact of antithymocyte globulin on the need for platelet transfusions during reduced-intensity conditioning administration before allogeneic stem cell transplantation. *Experimental Hematology*, **2013**, 41, 503-5	3.1	2
92	Identification of prognostic factors predicting outcome in Hodgkin lymphoma patients relapsing after autologous stem cell transplantation. *Annals of Oncology*, **2013**, 24, 2430-4	10.3	74
91	Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 940-8	4.7	17
90	Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. *Cancer*, **2013**, 119, 602-11	6.4	55
89	Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma. *Leukemia and Lymphoma*, **2013**, 54, 417-20	1.9	1
88	Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin lymphoma. *Bone Marrow Transplantation*, **2013**, 48, 249-52	4.4	14
87	Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT. *Bone Marrow Transplantation*, **2013**, 48, 794-8	4.4	6
86	Impact of pretransplant donor and recipient cytomegalovirus serostatus on outcome for multiple myeloma patients undergoing reduced intensity conditioning allogeneic stem cell transplantation. *Mediterranean Journal of Hematology and Infectious Diseases*, **2013**, 5, e2013026	3.2	11
85	Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?. *Bone Marrow Transplantation*, **2013**, 48, 305	4.4	2
84	Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. *Bone Marrow Transplantation*, **2013**, 48, 414-8	4.4	14

83	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. *Leukemia*, **2013**, 27, 2086-91	10.7	31
82	Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. *British Journal of Cancer*, **2013**, 109, 2523-32	8.7	20
81	Interplay effects between dose distribution quality and positioning accuracy in total marrow irradiation with volumetric modulated arc therapy. *Medical Physics*, **2013**, 40, 111713	4.4	25
80	Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma. *European Journal of Haematology*, **2012**, 88, 497-503	3.8	11
79	Successful treatment of post-transplant Epstein-Barr virus-related meningoencephalitis by intravenous rituximab monotherapy. *Leukemia and Lymphoma*, **2012**, 53, 2063-5	1.9	4
78	Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin lymphoma responding to prior salvage therapy. *Haematologica*, **2012**, 97, 1073-9	6.6	88
77	Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. *American Journal of Hematology*, **2012**, 87, 1074-8	7.1	20
76	ECIL 3-2009 update guidelines for antifungal management. *Bone Marrow Transplantation*, **2012**, 47, 866	4.4	7
75	Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. *Blood*, **2012**, 119, 1599-606	2.2	191
74	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. *Annals of Hematology*, **2012**, 91, 931-9	3	56
73	Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. *Experimental Hematology*, **2012**, 40, 521-7	3.1	33
72	JC Virus Leuko-Encephalopathy in Reduced Intensity Conditioning Cord Blood Transplant Recipient with a Review of the Literature. *Mediterranean Journal of Hematology and Infectious Diseases*, **2012**, 4, e2012043	3.2	5
71	The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. *Bone Marrow Transplantation*, **2012**, 47, 639-45	4.4	59
70	Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. *Expert Opinion on Biological Therapy*, **2012**, 12, 1505-15	5.4	12
69	Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?. *Leukemia and Lymphoma*, **2012**, 53, 1630-2	1.9	5
68	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. *Expert Opinion on Biological Therapy*, **2012**, 12, 1449-62	5.4	15
67	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. *Leukemia*, **2012**, 26, 1779-85	10.7	13
66	Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique. *Journal of Applied Clinical Medical Physics*, **2012**, 13, 3653	2.3	19

65	Do different conditioning regimens really make a difference?. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 237-45	3.1	14
64	Do different conditioning regimens really make a difference?. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 237-245	3.1	23
63	Prior rituximab administration is associated with reduced rate of acute GVHD after in´vivo T-cell depleted transplantation in lymphoma patients. *Experimental Hematology*, **2011**, 39, 892-6	3.1	14
62	Parvovirus B19 as an etiological agent of acute pleuro-pericarditis. *Bone Marrow Transplantation*, **2011**, 46, 317-8	4.4	6
61	Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT. *Bone Marrow Transplantation*, **2011**, 46, 1000-5	4.4	29
60	Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. *Annals of Oncology*, **2010**, 21, 1482-1485	10.3	16
59	Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. *Blood*, **2010**, 115, 3671-7	2.2	129
58	Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. *Leukemia and Lymphoma*, **2010**, 51, 1705-10	1.9	16
57	Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study. *Hematology/ Oncology and Stem Cell Therapy*, **2010**, 3, 167-73	2.7	16
56	Vertebroplasty for pain relief and spinal stabilization in multiple myeloma. *Neurological Sciences*, **2010**, 31, 151-7	3.5	19
55	Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. *Experimental Hematology*, **2010**, 38, 1241-50	3.1	33
54	Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. *Cancer*, **2010**, 116, 5001-11	6.4	30
53	Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. *British Journal of Haematology*, **2009**, 145, 369-72	4.5	46
52	Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. *Biology of Blood and Marrow Transplantation*, **2009**, 15, 432-8	4.7	24
51	Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease. *Leukemia and Lymphoma*, **2009**, 50, 80-4	1.9	13
50	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. *Blood*, **2009**, 113, 3375-82	2.2	81
49	Prospective Randomized Comparison of Reduced Intensity (FLU-BU-ATG) and Non-Myeloablative (FLU-TBI) Conditioning for Genoidentical Allo-SCT: a Clinical and economical Multicenter Itac Study.. *Blood*, **2009**, 114, 193-193	2.2	0
48	Comorbidities Index Is Not Predictive of Treatment Related Mortality in Patients (pts) Older Than 60 Years Treated with Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (RIC-ALLO).. *Blood*, **2009**, 114, 1180-1180	2.2	0

47	Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib. *Leukemia and Lymphoma*, **2007**, 48, 1015-8	1.9	6
46	Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. *Haematologica*, **2007**, 92, 418-20	6.6	13
45	Neutropenic Enterocolitis: Is There Aright Timing for Surgery? Assessment of a Clinical Case. *Tumori* , **2007**, 93, 608-610	1.7	5
44	Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin lymphoma: a monocenter prospective study. *American Journal of Hematology*, **2007**, 82, 122-7	7.1	21
43	IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin lymphoma patients. *Bone Marrow Transplantation*, **2007**, 40, 1019-25	4.4	16
42	Rituximab in thrombotic microangiopathy. *British Journal of Haematology*, **2007**, 139, 166; author reply 166-7	4.5	3
41	Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect?. *Therapeutic Apheresis and Dialysis*, **2007**, 11, 85-93	1.9	50
40	CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. *European Journal of Haematology*, **2007**, 78, 111-6	3.8	5
39	Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin disease after high-dose chemotherapy and autologous stem cell infusion. *European Journal of Haematology*, **2007**, 78, 322-9	3.8	19
38	Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin lymphoma. *Haematologica*, **2007**, 92, 35-41	6.6	169
37	Lymphomas. *Update on Cancer Therapeutics*, **2007**, 2, 101-110		1
36	Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients. *American Journal of Hematology*, **2006**, 81, 1-4	7.1	24
35	High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens. *Annals of Oncology*, **2006**, 17, 174-6	10.3	9
34	High-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients. *Annals of Oncology*, **2006**, 17, 719-20	10.3	
33	Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?. *Biology of Blood and Marrow Transplantation*, **2006**, 12, 1085-91	4.7	11
32	Lymphomas. *Update on Cancer Therapeutics*, **2006**, 1, 467-473		
31	Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications. *Supportive Care in Cancer*, **2006**, 14, 1141-6	3.9	6
30	What is the best option to cure patients with resistant/relapsing Hodgkin disease?. *Current Stem Cell Research and Therapy*, **2006**, 1, 419-24	3.6	3

29	High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin. *British Journal of Haematology*, **2005**, 129, 709-10	4.5	8
28	Lack of activity of allogeneic stem cell transplantation with reduced-intensity conditioning regimens in advanced sarcomas. *Bone Marrow Transplantation*, **2005**, 35, 421-2	4.4	7
27	Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up. *Bone Marrow Transplantation*, **2005**, 35, 1225	4.4	19
26	Primary mediastinal B-cell lymphoma with sclerosis: report of 11 cases treated with intensified-CHOP plus radiotherapy. *American Journal of Hematology*, **2005**, 78, 312-3	7.1	3
25	Lymphomas. *Cancer Chemotherapy and Biological Response Modifiers*, **2005**, 391-399		
24	Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-Fluorouracil-based chemotherapy?. *Oncologist*, **2004**, 9, 594-5; author reply 596	5.7	4
23	Nonmyeloablative allogenic peripheral-blood stem-cell transplantation in pancreatic adenocarcinoma: one case, high expectations. *Bone Marrow Transplantation*, **2004**, 33, 251	4.4	
22	Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen. *Bone Marrow Transplantation*, **2004**, 33, 1067-8	4.4	5
21	Intermediate-dose melphalan with stem-cell support in platinum-refractory ovarian cancer. *Bone Marrow Transplantation*, **2004**, 33, 1261-2	4.4	0
20	Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour. *British Journal of Cancer*, **2003**, 89, 1159-61	8.7	25
19	Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?. *Journal of Clinical Oncology*, **2003**, 21, 736-9	2.2	74
18	Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia. *Blood*, **2003**, 102, 2309; author reply 2309-10	2.2	2
17	Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution. *American Journal of Hematology*, **2003**, 73, 267-72	7.1	14
16	High-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly versus younger lymphoma patients: a matched analysis. *Leukemia and Lymphoma*, **2003**, 44, 1439-40	1.9	6
15	Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen. *Annals of Oncology*, **2003**, 14, 959-60	10.3	12
14	Lymphomas. *Cancer Chemotherapy and Biological Response Modifiers*, **2003**, 399-428		
13	Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas. *Bone Marrow Transplantation*, **2002**, 30, 207-14	4.4	7
12	High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. *Journal of Clinical Oncology*, **2002**, 20, 2181-8	2.2	60

11	Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. *Annals of Oncology*, **2002**, 13, 1341-6	10.3	21
10	Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. *Bone Marrow Transplantation*, **2001**, 28, 923-7	4.4	20
9	Allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in primary refractory prolymphocytic leukemia: graft-versus-leukemia effect without graft-versus-host disease. *Bone Marrow Transplantation*, **2001**, 28, 1155-6	4.4	3
8	Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate. *Annals of Oncology*, **2001**, 12, 953-5	10.3	36
7	Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patients. *Oncogene*, **2000**, 19, 2758-66	9.2	21
6	Allogeneic stem cell transplantation and non-myeloablative conditioning regimens. *Tumori*, **2000**, 86, S38-42	1.7	
5	Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT). *British Journal of Haematology*, **1998**, 103, 284-5	4.5	10
4	Les cytokines: outils et cibles privil□gi□s dans l□mmuno-surveillance du cancer. *Annales De L'Institut Pasteur / Actualit□s*, **1998**, 9, 121-130		
3	Maintained all-trans retinoic acid therapy in a patient with pseudotumour cerebri despite aggravated symptoms. *Leukemia and Lymphoma*, **1997**, 27, 373-4	1.9	10
2	Quantitative analysis of T helper 1, T helper 2, and inflammatory cytokine expression in patients after allogeneic bone marrow transplantation: relationship with the occurrence of acute graft-versus-host disease. *Transplantation*, **1997**, 63, 1307-13	1.8	29
1	Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. *Oncology*, **1993**, 50 Suppl 2, 47-52	3.6	11